The involvement of sphingolipids in multidrug resistance - PubMed (original) (raw)
Review
. 2001 Jun 1;181(3):153-62.
doi: 10.1007/s00232-001-0033-1.
Affiliations
- PMID: 11420602
- DOI: 10.1007/s00232-001-0033-1
Review
The involvement of sphingolipids in multidrug resistance
H Sietsma et al. J Membr Biol. 2001.
Abstract
Administration of most chemotherapeutic agents eventually results in the onset of apoptosis, despite the agents' variety in structure and molecular targets. Ceramide, the central molecule in cellular glycosphingolipid metabolism, has recently been identified as an important mediator of this process. Indeed, one of the events elicited by application of many cytotoxic drugs is an accumulation of this lipid. Treatment failure in cancer chemotherapy is largely attributable to multidrug resistance, in which tumor cells are typically cross-resistant to multiple chemotherapeutic agents. Different cellular mechanisms underlying this phenomenon have been described. Of these the drug efflux pump activity of P-glycoprotein and the multidrug resistance-associated proteins are the most extensively studied examples. Recently, an increased cellular capacity for ceramide glycosylation has been recognized as a novel multidrug resistance mechanism. Indeed, virtually all multidrug-resistant cells exhibit a deviating sphingolipid composition, most typically, increased levels of glucosylceramide. On the other hand, several direct molecular interactions between sphingolipids and drug efflux proteins have been described. Therefore, in addition to a role in the multidrug resistance phenotype by which ceramide accumulation and, thus, the onset of apoptosis are prevented, an indirect role for sphingolipids might be envisaged, by which the activity of these efflux proteins is modulated. In this review, we present an overview of the current understanding of the interesting relations that exist between sphingolipid metabolism and multidrug resistance.
Similar articles
- Sphingolipid metabolism enzymes as targets for anticancer therapy.
Kok JW, Sietsma H. Kok JW, et al. Curr Drug Targets. 2004 May;5(4):375-82. doi: 10.2174/1389450043345452. Curr Drug Targets. 2004. PMID: 15134220 Review. - Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias.
Salustiano EJ, da Costa KM, Freire-de-Lima L, Mendonça-Previato L, Previato JO. Salustiano EJ, et al. J Biol Chem. 2020 May 8;295(19):6457-6471. doi: 10.1074/jbc.RA120.013090. Epub 2020 Mar 30. J Biol Chem. 2020. PMID: 32229586 Free PMC article. - Differential expression of sphingolipids in MRP1 overexpressing HT29 cells.
Kok JW, Veldman RJ, Klappe K, Koning H, Filipeanu CM, Müller M. Kok JW, et al. Int J Cancer. 2000 Jul 15;87(2):172-8. doi: 10.1002/1097-0215(20000715)87:2<172::aid-ijc3>3.0.co;2-k. Int J Cancer. 2000. PMID: 10861470 - Ceramide glycosylation potentiates cellular multidrug resistance.
Liu YY, Han TY, Giuliano AE, Cabot MC. Liu YY, et al. FASEB J. 2001 Mar;15(3):719-30. doi: 10.1096/fj.00-0223com. FASEB J. 2001. PMID: 11259390 - Novel mechanisms of action of classical chemotherapeutic agents on sphingolipid pathways.
Hajj C, Becker-Flegler KA, Haimovitz-Friedman A. Hajj C, et al. Biol Chem. 2015 Jun;396(6-7):669-79. doi: 10.1515/hsz-2014-0302. Biol Chem. 2015. PMID: 25719313 Review.
Cited by
- The Drug Transporter P-Glycoprotein and Its Impact on Ceramide Metabolism-An Unconventional Ally in Cancer Treatment.
Ung J, Kassai M, Tan SF, Loughran TP Jr, Feith DJ, Cabot MC. Ung J, et al. Int J Mol Sci. 2024 Sep 11;25(18):9825. doi: 10.3390/ijms25189825. Int J Mol Sci. 2024. PMID: 39337312 Free PMC article. Review. - Coupling the role of lipids to the conformational dynamics of the ABC transporter P-glycoprotein.
De Vecchis D, Schäfer LV. De Vecchis D, et al. Biophys J. 2024 Aug 20;123(16):2522-2536. doi: 10.1016/j.bpj.2024.06.020. Epub 2024 Jun 21. Biophys J. 2024. PMID: 38909280 Free PMC article. - Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy.
Maines LW, Keller SN, Smith CD. Maines LW, et al. Int J Mol Sci. 2023 Nov 29;24(23):16901. doi: 10.3390/ijms242316901. Int J Mol Sci. 2023. PMID: 38069222 Free PMC article. - Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.
Ung J, Tan SF, Fox TE, Shaw JJP, Vass LR, Costa-Pinheiro P, Garrett-Bakelman FE, Keng MK, Sharma A, Claxton DF, Levine RL, Tallman MS, Cabot MC, Kester M, Feith DJ, Loughran TP Jr. Ung J, et al. Blood Rev. 2022 Sep;55:100950. doi: 10.1016/j.blre.2022.100950. Epub 2022 Apr 9. Blood Rev. 2022. PMID: 35487785 Free PMC article. Review. - Development of a Label-Free LC-MS/MS-Based Glucosylceramide Synthase Assay and Its Application to Inhibitors Screening for Ceramide-Related Diseases.
Fu Z, Yun SY, Won JH, Back MJ, Jang JM, Ha HC, Lee HK, Shin IC, Kim JY, Kim HS, Kim DK. Fu Z, et al. Biomol Ther (Seoul). 2019 Mar 1;27(2):193-200. doi: 10.4062/biomolther.2018.122. Biomol Ther (Seoul). 2019. PMID: 30231605 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources